Language: BG BG
nav.cta
Търсене, моля изчакайте...
Филтри
Статус
Фаза
Цел
Пол
Възраст
Държава
Филтри
Статус
Фаза
Цел
Пол
Възраст
Държава
AI · cancer
Намерени 1,748 изпитвания за "cancer" Стр. 40 от 88
Recruiting Phase 2
Phase II Study of RP2 as Immunoprevention in High-Risk Oral Precancerous Disease
High-Risk Oral Precancerous Disease

The goal of this study is to understand the safety, tolerability, and potential efficacy of an injected immune therapy called RP2 to treat oral precancer conditions and prevent progression to an oral cancer. The name of the study drug involved in this study is: -RP2 (a genetically modified live Herpes Simplex V-1 strain)

Начало: 01.01.2025 Край: 01.01.2029 Възраст: от 18 г.
United States Glenn J. Hanna NCT06623110
Recruiting
Immediate and Functional Results of Different Types of Reconstructions After Proximal Gastrectomy For Gastric and Esophagogastric Junction Cancer
Gastric Cancer (GC) Siewert Type III Adenocarcinoma of Esophagogastric Junction Siewert Type II Adenocarcinoma of Esophagogastric Junction

Proximal gastric and esophagogastric junction cancers comprise up to 40% of gastric malignancies. For localized disease, proximal gastrectomy is the main radical procedure, but reconstruction of GI tract often leads to significant functional issues. Rising use of proximal resections and broader indications have increased attention to postoperative quality of life (QoL). Common reconstructions include direct esophagogastrostomy (various types), double-tract reconstruction, jejunal interposition, and newer anti-reflux anastomoses (e.g., double-flap, overlap, tunnel techniques). Each method has unique pros and cons regarding reflux esophagitis, food passage, dumping syndrome, nutritional changes, and long-term QoL. No consensus exists on the optimal technique, leading to variable practices and outcomes. Most research focuses on oncologic radicality and survival, while functional results and QoL remain understudied. Systematic evaluation of functional outcomes across reconstruction types after proximal subtotal gastrectomy is needed in Russian Federation to improve QoL, advance research, and standardize treatment of proximal gastric and EGJ cancers.

Начало: 01.01.2025 Край: 01.06.2029 Възраст: от 18 г.
Russia P. Herzen Moscow Oncology Research Institute NCT07441785
Recruiting Phase 1
Study of IBI3009 in Participants with Unresectable, Metastatic or Extensive-Stage Small Cell Lung Cancer
Small Cell Lung Cancer

The main purpose of this study is to evaluate the safety and tolerability of IBI3009 and to determine the maximum tolerated dose (MTD) and/or the recommended dose for expansion (RDE) of IBI3009.

Начало: 30.12.2024 Край: 30.08.2027 Възраст: 18–75 г. Treatment
Australia, China Innovent Biologics (Suzhou) Co. Ltd. NCT06613009
Recruiting
STRatIfication of Vulvar SCC by HPV and p53 Status to Guide Excision
Vulvar Squamous Cell Carcinoma

This study is being done to answer the following question: Are there types of early-stage vulvar cancer that require either less or more treatment than the usual approach?

Начало: 10.12.2024 Край: 30.11.2031 Възраст: от 18 г. Treatment
Canada, New Zealand Canadian Cancer Trials Group NCT06358469
Recruiting Phase 3
Phase 3 Study of Xaluritamig vs Cabazitaxel or Second Androgen Receptor-Directed Therapy in Participants With Progressive Metastatic Castration-Resistant Prostate Cancer (XALute)
Metastatic Castration-resistant Prostate Cancer

The main objective of the study is to compare overall survival in participants receiving xaluritamig versus investigator's choice (cabazitaxel or second androgen receptor-directed therapy \[ARDT\]).

Начало: 09.12.2024 Край: 30.07.2029 Възраст: от 18 г. Treatment
Australia, Belgium, Canada +16 Amgen NCT06691984
Recruiting Phase 2
ctDNA-MRD Guided Consolidation Toripalimab in Stage IB-IIIA NSCLC
Lung Cancer, Nonsmall Cell

This study aims to incorporate circulating tumor DNA (ctDNA)-minimal residual disease (MRD) to personalize the administration of consolidation toripalimab therapy in resected stage IB-IIIA non-small-cell lung cancer (NSCLC) after adjuvant therapy. Toripalimab is a humanized monoclonal antibody for human programmed cell death protein 1. Toripalimab was approved as a consolidation treatment after perioperative therapy in combination with chemotherapy for resectable stage III NSCLC.

Начало: 01.12.2024 Край: 01.12.2029 Възраст: 18–75 г.
China Sun Yat-sen University NCT06426511
Recruiting Phase 3
A Phase Ⅲ Clinical Study of HLX22 in Combination With Trastuzumab and Chemotherapy for the Treatment of Gastroesophageal Junction and Gastric Cancer
Gastroesophageal-junction Cancer Monoclonal Antibody Gastric Cancer HER2-positive Gastric Cancer

This is a double-blind, randomized, multiregion, comparative phase Ⅲ clinical study designed to evaluate the efficacy and safety of HLX22 in combination with trastuzumab and chemotherapy as first-line treatment in patients with HER2-positive locally advanced/metastatic adenocarcinoma of the gastric and/or gastroesophageal junction (G/GEJ).Eligible subjects will be randomized to the two groups based on a 1:1 ratio. Enrolled subjects shall be treated with the study drug until the loss of clinical benefit, death, intolerable toxicity, withdrawal of informed consent, or other reasons specified by the protocol (whichever occurs first).

Начало: 22.11.2024 Край: 01.09.2028 Възраст: от 18 г. Treatment
Argentina, Australia, Brazil +14 Shanghai Henlius Biotech NCT06532006
Recruiting Phase 3
Atezolizumab, Pertuzumab and Trastuzumab with chemotherapy as neoadjuvant treatment of HER2 positive early high-risk and locally advanced breast cancer (APTneo)
Invasive Breast Cancer

Trial status: Authorised Pathological Complete Response (pCR), Relationship between pCR and EFS, Clinical Overall Response (cOR) at the end of neo-adjuvant treatment, Disease-Free Survival (DFS), Distant Event Free Survival, Overall Survival Event Free Survival (EFS)

Начало: 21.11.2024 Възраст: от 18 г.
Austria, Belgium, Germany +3 Fondazione Michelangelo 2024-518026-32-00
Recruiting Phase 2
Efficacy and Safety of Serplulimab Combined With Chemotherapy as Neoadjuvant Treatment for Locally Advanced Gastric Cancer or Adenocarcinoma of Esophagogastric Junction
Stomach Neoplasms Immune Checkpoint Inhibitors

This is a multicenter, double-blind, randomized, phase 2 trial to investigate the efficacy and safety of serlulimab combined with nab-paclitaxel plus SOX versus nab-paclitaxel plus SOX alone as neoadjuvant treatment for locally advanced GC or AEG. The goal of this clinical trial is to learn if serlulimab combined with nab-paclitaxel plus SOX as neoadjuvant treatment for locally advanced AEG/GC. It will also learn about the safety of serlulimab combined with nab-paclitaxel plus SOX. The main questions it aims to answer are: Does serlulimab increase the pCR of participants with locally advanced AEG/GC ? What medical problems do participants have when taking serlulimab? Researchers will compare to a placebo (a look-alike substance that contains no drug) to see if serlulimab combined with nab-paclitaxel plus SOX as neoadjuvant treatment for locally advanced AEG/GC. Participants will: Eligible patients were randomly assigned to receive serlulimab (4.5 mg intravenously on day 1) combined with chemotherapy (nap-paclitaxel 260 mg/m2 intravenously on days 1, OXA 130mg/ /m2, intravenously on days 1, and S-1 40 to 60 mg orally twice daily depending on BSA on days 1 to 14) or chemotherapy alone every 3 weeks for 3 preoperative cycles followed by 3 postoperative cycles. All patients will be followed for survival.

Начало: 15.11.2024 Край: 30.09.2026 Възраст: 18–75 г.
China Xijing Hospital NCT06576921
Recruiting Phase 1
A Study to Evaluate Safety, Pharmacokinetics, and Activity of GDC-7035 as a Single Agent and in Combination in Patients With Advanced Solid Tumors
Solid Tumor

This is a first-in-human Phase I/II, open-label, multicenter, dose-escalation and expansion study designed to evaluate the safety, pharmacokinetics, and preliminary activity of GDC-7035 as a single agent and in combination with other anti-cancer therapies in participants with advanced or metastatic solid tumors that harbor the KRAS G12D mutation.

Начало: 14.11.2024 Край: 31.05.2028 Възраст: от 18 г. Treatment
Australia, Canada, Israel +5 Genentech, Inc. NCT06619587
Recruiting Phase 2
Neoadjuvant Umbrella Trial for Patients With Unresectable Stage III NSCLC Harboring Rare Mutations.
Lung Cancer Stage III Mutation

This umbrella trial directed by next generation sequencing (NGS) includes patients with treatment-naive unresectable stage III non-small-cell lung cancer (NSCLC). The aim of the umbrella study is to evaluate the efficacy of induction NGS-directed targeted therapies followed by surgery for stage III NSCLC patients whose tumor harbors a rare mutation.

Начало: 01.11.2024 Край: 01.11.2029 Възраст: 18–75 г.
China Sun Yat-sen University NCT06563999
Recruiting Phase 2
Evaluation of the Possible Safety and Efficacy of Dapagliflozin in the Prophylaxis of Doxorubicin-Induced Cardiotoxicity
Doxorubicin Induced Cardiomyopathy Breast Cancer

This is a randomized controlled clinical trial that aims to evaluate the safety and efficacy of Dapagliflozin as a cardioprotective in doxorubicin-induced cardiotoxicity in breast cancer patients.

Начало: 31.10.2024 Край: 01.10.2026 Възраст: 18–65 г.
Egypt Tanta University NCT06427226
Recruiting
Barrigel® PPRT (Post-Prostatectomy Radiation Therapy) Trial
Prostate Cancer

Barrigel is intended to temporarily position the anterior rectal wall away from the prostate or prostate bed during radiotherapy treatment for prostate cancer and, in creating this space, it is the intent of Barrigel to reduce the radiation dose delivered to the anterior rectum.

Начало: 31.10.2024 Край: 31.12.2027 Възраст: от 18 г. Prevention
Australia, United States Palette Life Sciences, Inc. NCT06496256
Recruiting Phase 1
89Zr-olaratumab Dosimetry in Participants With Soft Tissue Sarcoma
Soft Tissue Sarcoma

Soft Tissue Sarcoma (STS) is a type of cancer that develops in soft tissues such as muscles, tendons, fat, blood vessels, and nerves. STSs generally express a protein called Platelet-Derived Growth Factor Receptor (PDGFR)α, which makes them a target for the development of STS therapies, such as olaratumab. Olaratumab has been identified as a promising candidate to which radioactive substances can be attached for imaging or therapeutic purposes. Thus, this first in human imaging trial aims to study olaratumab combined with a radioactive metal called zirconium-89 (89Zr-TLX300-CDx) as a potential new product that may be used for STS imaging and identification of patients that may benefit from future treatments targeting PDGFRα.

Начало: 31.10.2024 Край: 01.08.2026 Възраст: от 18 г. Diagnostic
Australia Telix Pharmaceuticals (Innovations) Pty Ltd NCT06537596
Recruiting Phase 1
Open-Label Study of BBO-10203 in Subjects With Advanced Solid Tumors
Solid Tumor, Adult Metastatic Breast Cancer Advanced Breast Cancer HER2 Mutation-Related Tumors +7

First in human study to evaluate the safety, tolerability, and pharmacokinetics (PK) of BBO-10203, a PI3Kα:RAS breaker, alone and in combination with other anti-cancer agents in patients with advanced solid tumors.

Начало: 29.10.2024 Край: 01.11.2028 Възраст: от 18 г. Treatment
Australia, France, Spain +1 TheRas, Inc., d/b/a BBOT (BridgeBio Oncology Therapeuti NCT06625775
Recruiting Phase 3
A Study to Learn How PF-06821497 (Mevrometostat) Works in Men With Metastatic Castration-resistant Prostate Cancer.
Metastatic Castration-Resistant Prostate Cancer

This study will explore whether a combination of the investigational drug PF-06821497 and enzalutamide will work better than taking enzalutamide alone in participants with mCRPC who are ARSi or abiraterone naïve.

Начало: 22.10.2024 Край: 30.11.2028 Възраст: от 18 г. Treatment
Argentina, Brazil, Bulgaria +23 Pfizer NCT06629779
Recruiting Phase 1
Subcutaneous Tarlatamab in Participants With Extensive Stage Small Cell Lung Cancer (DeLLphi-308)
Extensive Stage Small Cell Lung Cancer

The primary objective of this study is to evaluate the safety and tolerability of subcutaneous (SC) tarlatamab.

Начало: 07.10.2024 Край: 27.03.2030 Възраст: от 18 г. Basic science
Australia, Belgium, China +7 Amgen NCT06598306
Recruiting Phase 3
A Study to Investigate the Efficacy and Safety of Dato-DXd With or Without Osimertinib Compared With Platinum Based Doublet Chemotherapy in Participants With EGFR-Mutated Locally Advanced or Metastatic Non-Small Cell Lung Cancer
Metastatic Non-small Cell Lung Cancer

This study will assess the effect of Dato-DXd in combination with osimertinib or Dato-DXd monotherapy versus platinum-based doublet chemotherapy in terms of progression-free survival (PFS).

Начало: 04.10.2024 Край: 27.09.2028 Възраст: 18–130 г. Treatment
Australia, Belgium, Brazil +23 AstraZeneca NCT06417814
Recruiting Phase 3
A Trial to Evaluate Intravesical Nadofaragene Firadenovec Alone or in Combination With Chemotherapy or Immunotherapy in Participants With High-grade BCG Unresponsive Non-muscle Invasive Bladder Cancer
Non-muscle Invasive Bladder Cancer With Carcinoma in Situ

The pivotal phase 3 trial (rAd-IFN-CS 003) evaluating the efficacy of nadofaragene firadenovec showed that 55 (53.4%) of 103 subjects with CIS ± high-grade Ta/T1 achieved a complete response (CR) at 3 months. In this trial, the safety and efficacy of intravesical instillation of nadofaragene firadenovec alone or in combination with chemotherapy or immunotherapy will be evaluated in participants with NMIBC CIS (± high-grade Ta/T1).

Начало: 01.10.2024 Край: 31.12.2030 Възраст: от 18 г.
Canada, Czechia, France +4 Ferring Pharmaceuticals NCT06545955
Recruiting Phase 3
A Phase 3 Study to Evaluate Petosemtamab Plus Pembrolizumab vs Pembrolizumab in First-line Treatment of Head and Neck Cancer (LiGeR - HN1)
Head and Neck Squamous Cell Carcinoma

This is a Phase 3 randomized, open-label study to evaluate the efficacy and safety of petosemtamab plus pembrolizumab vs pembrolizumab in first-line treatment of recurrent or metastatic PD-L1+ head and neck squamous cell carcinoma.

Начало: 25.09.2024 Край: 01.07.2030 Възраст: от 18 г. Treatment
Argentina, Australia, Belgium +23 Merus B.V. NCT06525220
1 … 38 39 40 41 42 … 88